/Companies

Implican

3 known investors

Find your way into Implican

166 people in our graph can introduce you to the Implican team.

Sign up to see every warm intro you have to Implican

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Implican team. We find them
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes you can't see from your own inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Implican is developing a patented anastomotic device that uses two compression rings to fixate bowel walls during colorectal surgery, aiming to achieve primary wound healing and reduce anastomotic leakage. The device targets surgeons treating colorectal cancer patients as an alternative to circular staplers, and is in preclinical/clinical testing.

Founders & leadership

RKRik Kielman
Rik KielmanChief Executive Officer (CEO)Rik Kielman previously held a commercial strategy role at Sensius, where he developed market access strategies for European and US clinics and directed reimbursement efforts, before joining Implican as CEO to oversee regulatory, clinical, and market strategy for the company's anastomotic fixation device.
IKIvo Kooijman
Ivo KooijmanChief Technology Officer (CTO)Ivo Kooijman is CTO of Implican, a medical device company developing an anastomotic device for colorectal surgery.
KHKlaas Havenga
Klaas HavengaChief Medical Officer (CMO)

Investors · 3

Frequently asked questions

What does Implican do?
Implican is developing a patented anastomotic device that uses two compression rings to fixate bowel walls during colorectal surgery, aiming to achieve primary wound healing and reduce anastomotic leakage. The device targets surgeons treating colorectal cancer patients as an alternative to circular staplers, and is in preclinical/clinical testing.
Who are Implican's investors?
Implican's investors include NextGen Ventures, NV NOM, Nom.